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EDITORIAL
The  road to  eliminate  mother-to-child  HIV
transmission,
O  caminho  para  eliminac¸ão  da  transmissão  vertical  do  HIV
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The  World  Health  Organization’s  Global  Health  Observatory
estimates  that  78  million  people  have  been  infected  with
the  human  immunodeﬁciency  virus  (HIV)  during  the  course  of
the  epidemic,  and  that  39  million  men,  women,  and  children
have  died.1 Nearly  1  in  20  adults  in  sub-Saharan  Africa  are
currently  living  with  the  infection.  HIV  represents  one  of  the
world’s  most  serious  health  problems.
The  WHO  global  health  sector  strategy  on  HIV/acquired
immunodeﬁciency  syndrome  (AIDS)  has  identiﬁed  four
strategic  directions  to  guide  countries’  HIV  response  to
achieve  the  United  Nations’  Millennium  Development  Goal
of  halting  the  spread  of  HIV/AIDS.  A  core  element  of  strate-
gic  direction  one  was  the  elimination  of  new  HIV  infections
in  children.2
It  is  encouraging  that  the  number  of  new  HIV  infec-
tions  in  children  is  decreasing  in  most  parts  of  the  world.
In  2011,  there  were  approximately  330,000  new  childhood
infections,  and  while  this  is  a  reduction  of  43%  since  2003,
it  remains  unacceptably  high.3 Unfortunately,  increased
childhood  infection  rates  were  observed  in  Angola,  Congo,
Equatorial  Guinea,  and  Guinea-Bissau.While  a  small  proportion  of  childhood  infections  result
from  blood  transfusions,  sexual  abuse,  or  unsafe  injecting
practices,  the  main  cause  is  mother-to-child  transmission
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MTCT),3,4 which  may  happen  in-utero,  peripartum,  or
hrough  breastfeeding.
Sixteen  million  women  were  living  with  HIV  at  the  end  of
0135 and  many  are  of  reproductive  age.  A  total  of  1,600,000
regnancies  are  complicated  by  HIV  infection  worldwide,
nd  MTCT  rates,  in  the  absence  of  therapeutic  intervention,
re  estimated  to  be  as  high  as  31%.6 Conditions  resulting
n  placental  inﬂammation,  age  at  ﬁrst  sexual  intercourse,
nd  genital  ulcer  disease  are  associated  with  higher  rates  of
TCT.
Substantial  improvements  in  the  rates  of  MTCT  have  been
chieved  since  the  ﬁrst  case  of  HIV  MTCT  was  identiﬁed  in
983.  Routine  HIV  screening  in  pregnancy  has  been  recom-
ended  since  the  late  1990s;  clinical  trials  of  antiretrovirals
ave  demonstrated  safe,  efﬁcacious  regimens  during  preg-
ancy,  and  funds  have  been  directly  allocated  for  research
n  MTCT.
Treatment  of  pregnant  women  with  combination
ntiretroviral  therapy  (cART)  has  lead  to  a  dramatic  impact
n  MTCT.7 cART  was  shown  to  reduce  MTCT  by  almost
0-fold.  It  is  estimated  that  between  2009  and  2011,  cART
rovided  in  pregnancy  prevented  409,000  childhood  HIV
nfections.3 In  response  to  the  weight  of  evidence  for  pre-
ention  of  MTCT,  the  WHO  Consolidated  Guidelines  on  the
se  of  Antiretroviral  Drugs  for  Treating  and  Preventing  HIV
nfection  recommends  that  all  pregnant  and  breastfeeding
omen  with  HIV  should  be  commenced  on  antiretroviral
herapy  and  those  meeting  eligibility  criteria  should  receive
ifelong  treatment.8
It  is  believed  that  elimination  of  MTCT  can  be  achieved
hrough  effective  antiretroviral  coverage,  education,
nd  appropriate  supportive  care.  However,  antiretroviral
dade Brasileira de Pediatria.
5c
o
t
m
u
s
t
i
o
l
p
1
f
t
e
h
0
2
i
3
d
t
t
m
a
a
l
1
o
y
f
c
c
H
s
s
H
p
a
w
d
a
t
a
d
t
t
s
a
p
i
o
e
d
f
l
C
w
a
t
p
c
o
(
n
t
l
c
m
o
n
i
i
c
a
b
w
o
t
M
i
w
i
t
c
w
b
p
(
a
T
e
m
c
f
p
r
>
S
T
n
p
R
w
p
w
o
f
i10  
overage  of  pregnant  women  with  HIV  remains  poor,  with
nly  30%  of  eligible  pregnant  women  receiving  antiretroviral
herapy  (ART),  as  opposed  to  54%  for  all  eligible  adults.3 The
ajority  of  HIV-infected  infants  are  born  to  mothers  who  are
naware  of  their  HIV  status,4 highlighting  the  importance  of
creening  programmes  during  pregnancy.
As  a  developing  country,  Brazil  bears  a  heavy  burden  of
he  HIV  epidemic,  and  has  made  signiﬁcant  progress  in  halt-
ng  the  spread  of  the  infection.  Brazil  has  a  stable  prevalence
f  HIV  estimated  at  1%,  with  approximately  718,000  people
iving  with  the  virus.  The  prevalence  of  HIV  infection  in  key
opulations  in  Brazil  is  estimated  at  5.9%  among  drug  users,
0.5%  among  men  who  have  sex  with  men,  and  4.9%  among
emale  commercial  sex  workers.9
In  2012,  8622  cases  of  AIDS  were  reported  in  women
hrough  the  SINAN  information  system  for  notiﬁable  dis-
ases.  Exposure  in  these  women  was  determined  as  96.6%
eterosexual,  2.5%  intravenous  drug  use,  0.8%  MTCT,  and
.1%  via  transfusion.  In  the  ten  years  between  2003  and
012,  the  age  of  patients  with  AIDS  has  shifted  to  younger
ndividuals,  with  highest  rates  observed  in  patients  aged
0--49  years  of  age.  There  has  been  an  increasing  trend  in
etection  rates  among  people  aged  15--24  years,9 increasing
he  proportion  of  women  at  reproductive  age  with  HIV.
The  Brazilian  population  is  well-informed  regarding  the
ransmission  of  HIV:  large-scale  surveys  show  a  97%  agree-
ent  to  the  statement  that  condom  use  is  the  best  way  to
void  HIV  infection.  Unfortunately,  this  does  not  translate
s  well  as  would  be  hoped  to  action,  with  only  55%  preva-
ence  of  condom  use  with  a  casual  partner  in  the  previous
2  months  in  people  aged  15--65  years.9
There  has  been  an  overall  decrease  in  the  detection  rate
f  AIDS  amongst  children  under  5  years  (35.8%)  over  the  ten
ears  preceding  2012.  This  reduction  was  not  observed  uni-
ormly  across  Brazil,  and  increases  in  notiﬁcations  of  AIDS  in
hildren  were  seen  in  the  North  and  Northeast  regions.9
MTCT  remains  the  major  route  of  acquisition  of  HIV  for
hildren  under  5  years  of  age  in  Brazil.  Identiﬁcation  of
IV  in  pregnancy  is  improving  in  Brazil,  with  an  estimated
creening  coverage  of  80%  in  a  recent  study  in  women  pre-
enting  for  pre-natal  testing.10 However,  it  is  estimated  that
IV  testing  only  reaches  58.3%  of  the  expected  cases  of  HIV-
ositive  pregnant  women.9 HIV  in  pregnancy  was  estimated
t  0.38%  prevalence  in  Brazil,  with  50.7%  of  those  infected
ith  HIV  aged  between  20  and  29  years.
The  article  by  da  Rosa  et  al.,11 in  this  issue  of  Jornal
e  Pediatria,  presents  a  retrospective  evaluation  of  rates  of
nd  factors  associated  with  MTCT  of  HIV-1  at  a  large  hospi-
al  in  Southern  Brazil  over  a  14-year  period,  between  1998
nd  2011.  The  authors  extracted  data  from  the  laboratory
atabase  and  medical  records  for  this  purpose,  and  split
he  time  into  two  sections  for  comparison.  They  reported
hat  there  had  been  a  change  in  the  prevalence  of  viral
ubtype  C  and  in  clinical  management  of  HIV  over  time,
lthough  the  exact  parameters  of  these  changes  were  not
resented.
During  that  period,  there  were  353  live  births  to  HIV-
nfected  women.  There  was  a  reduction  in  the  rate  of  MTCT
f  HIV  from  11.8%  to  3.2%  over  the  two  periods.  The  differ-
nce  was  highly  signiﬁcant,  both  statistically  and  clinically,
ramatically  altering  the  lives  of  the  children  protected
rom  HIV  infection.  The  authors  found  that  the  rates  of
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ow  maternal  viral  load  (<1000  copies/mL),  high  maternal
D4+ T  cell  count  (>500  ×  109 cells/mL),  and  use  of  ART  that
as  deemed  complete  (maternal  ART  during  pregnancy  and
t  delivery  and  zidovudine  post  exposure  prophylaxis  for
he  neonate)  increased  from  the  ﬁrst  to  the  second  time
eriod.  It  was  also  observed  that  management  of  labour
hanged  over  the  two  periods,  with  membrane  rupture  times
f  greater  than  4  h  being  the  norm  in  the  earlier  period
79.4%),  but  not  during  the  later  period  (27%).  There  was
ot  a  signiﬁcant  change  in  the  route  of  delivery  over  this
ime,  however  it  is  likely  that  the  change  in  management  of
abour  reﬂects  national  health  department  policy.
The  retrospective  nature  of  the  study  prevents  ﬁrm
onclusions  being  drawn  regarding  the  cause  of  the  dra-
atic  fall  in  MTCT.  It  is  likely  that  the  fall  in  MTCT  seen
ver  the  time  evaluated  in  this  study  is  due  to  a  combi-
ation  of  factors,  but  that  it  is  dominated  by  the  increase
n  the  proportion  of  women  with  low  HIV  viral  load,  which
n  turn  is  due  to  higher  rates  of  pregnant  women  receiving
ART.  Prevention  of  MTCT  is  one  of  the  beneﬁts  of  treatment
s  prevention,  and,  as  the  implementation  of  this  policy
ecomes  more  widespread,  both  in  Brazil  and  worldwide,
e  can  expect  to  see  prevention  of  disease  and  prevention
f  transmission  both  to  children  of  HIV-infected  mothers  and
o  sexual  partners  of  PLHIV.
A  range  of  interventions  are  recommended  to  prevent
TCT  as  outlined  in  international  guidelines.12,13 The  major-
ty  of  these  interventions  are  being  applied  in  Brazil,
ith  admirable  timeliness,  including  identiﬁcation  of  HIV
nfection  in  pregnant  women  by  screening  during  antena-
al  care;  engaging  and  retaining  HIV-infected  women  in
are;  recommending  and  making  available  cART  for  these
omen;  screening  for  and  treating  other  sexually  transmissi-
le  infections  in  women  at  risk;  and  providing  post  exposure
rophylaxis  for  children  of  HIV-infected  mothers.9
Evidence  concerning  the  impact  on  MTCT  of  prolonged
>4  h)  rupture  of  membranes  was  evaluated  in  a  meta-
nalysis  in  2001  by  the  International  Perinatal  HIV  Group.14
his  identiﬁed  an  increase  in  the  risk  of  MTCT  of  2%  for
ach  hour  of  membrane  rupture.  In  contrast,  a  smaller,
ore  recent  study  of  707  women  who  received  prenatal
are  including  ART  at  a  single  centre  in  Miami,  Cotter  et  al.
ound  no  cases  of  perinatal  transmission  in  women  with
lasma  viral  loads  of  <1000  HIV  copies/mL  with  membrane
upture  for  up  to  25  h.15 In  this  cohort,  only  viral  load
10,000  copies/mL  was  an  independent  risk  factor  for  MTCT.
o  what  is  the  difference  here?  It  would  appear  to  be  cART.
he  studies  included  in  the  meta-analysis  were  predomi-
antly  conducted  prior  to  the  availability  of  cART,  while  the
atients  in  the  Miami  study  were  receiving  cART.  While  da
osa  et  al.11 found  that  prolonged  rupture  of  membranes
as  a  risk  factor  for  transmission,  it  is  likely  to  be  much  less
otent  a factor  than  uncontrolled  HIV  viraemia.  For  women
ho  have  not  achieved  virological  suppression  at  the  time
f  delivery,  it  is  likely  that  elective  caesarean  section  or,
ailing  that,  avoidance  of  prolonged  rupture  of  membranes
s  still  indicated.
Despite  the  fall  in  MTCT  observed  in  this  study  and  else-
here,  the  rate  is  still  too  high.  We  all  need  to  work  to
educe  the  transmission  rate  to  zero.  Some  of  the  strate-
ies  needed  to  achieve  this  are  known,  as  listed  above,
nd  require  energetic  implementation  and  support.  Some,
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such  as  the  engagement  and  retention  in  care  of  individ-
uals  who  use  injectable  drugs,  are  more  challenging.  It  is
encouraging  to  see  the  efforts  and  funding  for  this  group
being  prioritized  in  Brazil.9 Women  who  have  HIV  infection
diagnosed  during  pregnancy  are  a  key  focal  group,  as  there
is  less  time  between  treatment  initiation  and  delivery  to
achieve  virological  suppression  to  prevent  MTCT.  Also,  treat-
ment  adherence  is  a  key  issue  in  HIV  care  for  all  patients,
but,  as  identiﬁed  in  a  recent  review,  less  than  three  quarters
of  pregnant  women  have  optimal  treatment  adherence.16
Whether  this  reﬂects  uncertainty  about  the  safety  of  medi-
cations  for  the  foetus  or  lack  of  engagement  with  care,  this
also  represents  a  key  area  for  attention  to  end  HIV  transmis-
sion.
The  ﬁndings  of  this  study,  along  with  the  results  from  the
START  study  showing  the  clear  individual  health  beneﬁt  of
early  treatment,17 tell  us  that  rather  than  calling  for  more
research,  it  is  now  time  to  implement  what  we  already  know
to  achieve  the  goal  of  an  HIV-free  generation.
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